{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:18Z","timestamp":1790352198153,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202201011346"],"award-info":[{"award-number":["202201011346"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01640-z","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T08:37:13Z","timestamp":1743755833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of the efficacy and safety of belimumab and telitacicept in patients with systemic lupus erythematosus: results from a retrospective, observational study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0831-6678","authenticated-orcid":false,"given":"Tianxiao","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3443-0521","authenticated-orcid":false,"given":"Manyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-7087","authenticated-orcid":false,"given":"Jieying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-048X","authenticated-orcid":false,"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-5571","authenticated-orcid":false,"given":"Yang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"1","key":"1640_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.12660","volume":"284","author":"CM Tipton","year":"2018","unstructured":"Tipton CM, Hom JR, Fucile CF, Rosenberg AF, Sanz I. Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: AB-cell immunomics approach. Immunol Rev. 2018;284(1):120\u201331.","journal-title":"Immunol Rev"},{"issue":"10188","key":"1640_CR2","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332\u201343.","journal-title":"Lancet"},{"issue":"6","key":"1640_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF\/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365\u201373.","journal-title":"Nat Rev Rheumatol"},{"key":"1640_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102873","volume":"132","author":"L Arbitman","year":"2022","unstructured":"Arbitman L, Furie R, Vashistha H. B cell-targeted therapies in systemic lupus erythematosus. J Autoimmun. 2022;132: 102873.","journal-title":"J Autoimmun"},{"issue":"9767","key":"1640_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"},{"issue":"4","key":"1640_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1640_CR7","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/biomedicines11030962","volume":"11","author":"F Sun","year":"2023","unstructured":"Sun F, Wu H, Wang Z, et al. Effectiveness and safety of belimumab in Chinese lupus patients: a multicenter, real-world observational study. Biomedicines. 2023;11(3):962.","journal-title":"Biomedicines"},{"issue":"2","key":"1640_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001074","volume":"10","author":"HZ Jin","year":"2023","unstructured":"Jin HZ, Li YJ, Wang X, et al. Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med. 2023;10(2): e001074.","journal-title":"Lupus Sci Med"},{"issue":"3","key":"1640_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","volume":"18","author":"AR Parra S\u00e1nchez","year":"2022","unstructured":"Parra S\u00e1nchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146\u201357.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1640_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8(1): e000538.","journal-title":"Lupus Sci Med"},{"issue":"2","key":"1640_CR11","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019;1(2):e95\u2013102.","journal-title":"Lancet Rheumatol"},{"key":"1640_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13075-017-1451-5","volume":"19","author":"M Piga","year":"2017","unstructured":"Piga M, Floris A, Cappellazzo G, et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther. 2017;19:247.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1640_CR13","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2665-9913(24)00121-8","volume":"6","author":"V Golder","year":"2024","unstructured":"Golder V, Kandane-Rathnayake R, Li N, et al. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study. Lancet Rheumatol. 2024;6(8):e528\u201336.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"1640_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","volume":"78","author":"S Oon","year":"2019","unstructured":"Oon S, Huq M, Golder V, et al. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(5):629\u201333.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1640_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-024-03389-4","volume":"26","author":"Z Su","year":"2024","unstructured":"Su Z, Zhang C, Gao C, et al. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study. Arthritis Res Ther. 2024;26(1):163.","journal-title":"Arthritis Res Ther"},{"key":"1640_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117\u201328.","journal-title":"N Engl J Med"},{"key":"1640_CR17","doi-asserted-by":"publisher","first-page":"1423035","DOI":"10.3389\/fimmu.2024.1423035","volume":"15","author":"C Fan","year":"2024","unstructured":"Fan C, Yang T, Zheng S, et al. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: a real-life, single-center observational study. Front Immunol. 2024;15:1423035.","journal-title":"Front Immunol"},{"key":"1640_CR18","first-page":"1","volume":"44","author":"HZ Jin","year":"2024","unstructured":"Jin HZ, Cai ML, Wang X, et al. Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study. Clin Rheumatol. 2024;44:1\u201310.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1640_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1640_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3899\/jrheum.160214","volume":"45","author":"H-L Chen","year":"2018","unstructured":"Chen H-L, Shen L-J, Hsu P-N, Shen C-Y, Hall S, Hsiao F-Y. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018;45(1):83\u20139.","journal-title":"J Rheumatol"},{"issue":"Supple5","key":"1640_CR21","doi-asserted-by":"publisher","first-page":"v39","DOI":"10.1093\/rheumatology\/keaa381","volume":"59","author":"M Gasparotto","year":"2020","unstructured":"Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology. 2020;59(Supple5):v39\u201351.","journal-title":"Rheumatology"},{"issue":"9","key":"1640_CR22","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","volume":"28","author":"X Huang","year":"2024","unstructured":"Huang X, Lin F, Chen H. Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study. Clin Exp Nephrol. 2024;28(9):902\u20139.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1640_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000078","volume":"2","author":"A Fayyaz","year":"2015","unstructured":"Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015;2(1): e000078.","journal-title":"Lupus Sci Med"},{"issue":"7","key":"1640_CR24","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s10067-024-06992-7","volume":"43","author":"J Cheng","year":"2024","unstructured":"Cheng J, Peng Y, Wu Q, et al. Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement. Clin Rheumatol. 2024;43(7):2229\u201336.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"1640_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/09612033241241576","volume":"33","author":"Q Wu","year":"2024","unstructured":"Wu Q, Zhao M-X, Huang X-S, Lin C-S, Xu Q. The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: a retrospective cohort study. Lupus. 2024;33(6):608\u201314.","journal-title":"Lupus"},{"issue":"9","key":"1640_CR26","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3899\/jrheum.100007","volume":"37","author":"AJ Steiman","year":"2010","unstructured":"Steiman AJ, Gladman DD, Iba\u00f1ez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol. 2010;37(9):1822\u20137.","journal-title":"J Rheumatol"},{"issue":"1S","key":"1640_CR27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin BH, Ayoub IM, Chan TM, et al. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1S):S1\u201369.","journal-title":"Kidney Int"},{"issue":"1","key":"1640_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"key":"1640_CR29","doi-asserted-by":"crossref","unstructured":"Merrill JT, Wallace DJ, Wax S, et al. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-\nControlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018;70(2):266-276.","DOI":"10.1002\/art.40360"},{"issue":"5","key":"1640_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00393-023-01461-z","volume":"83","author":"Q Fan","year":"2024","unstructured":"Fan Q, Yang H, Liu Y. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab\u202f: a case series. Z Rheumatol. 2024;83(5):387\u201392.","journal-title":"Z Rheumatol"},{"issue":"3","key":"1640_CR31","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","volume":"63","author":"D Xu","year":"2024","unstructured":"Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology (Oxford). 2024;63(3):698\u2013705.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01640-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01640-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01640-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:55Z","timestamp":1764917455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01640-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01640-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Boards of Guangdong Academy of Medical Sciences (ID: S2024-170-02). Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"105"}}